Gulf International Bank UK Ltd Sells 92 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Gulf International Bank UK Ltd decreased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 8,424 shares of the biopharmaceutical company’s stock after selling 92 shares during the period. Gulf International Bank UK Ltd’s holdings in Regeneron Pharmaceuticals were worth $6,000,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. SteelPeak Wealth LLC grew its holdings in shares of Regeneron Pharmaceuticals by 1.5% in the 3rd quarter. SteelPeak Wealth LLC now owns 1,108 shares of the biopharmaceutical company’s stock worth $1,165,000 after purchasing an additional 16 shares during the last quarter. Oak Harvest Investment Services boosted its position in Regeneron Pharmaceuticals by 25.6% in the third quarter. Oak Harvest Investment Services now owns 2,779 shares of the biopharmaceutical company’s stock valued at $2,921,000 after buying an additional 567 shares in the last quarter. Fairfield Financial Advisors LTD bought a new stake in Regeneron Pharmaceuticals during the third quarter worth about $37,000. LCM Capital Management Inc increased its holdings in shares of Regeneron Pharmaceuticals by 4.6% during the third quarter. LCM Capital Management Inc now owns 543 shares of the biopharmaceutical company’s stock worth $571,000 after buying an additional 24 shares in the last quarter. Finally, Focus Financial Network Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 7.4% during the third quarter. Focus Financial Network Inc. now owns 538 shares of the biopharmaceutical company’s stock worth $566,000 after buying an additional 37 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $702.78 on Friday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $76.83 billion, a P/E ratio of 18.36, a PEG ratio of 2.34 and a beta of 0.08. The business has a 50-day moving average of $698.57 and a 200-day moving average of $873.11. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $11.86 earnings per share. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.50%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on REGN shares. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Oppenheimer lowered their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Finally, Bank of America restated an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.